10-Q · June 15, 2026
enGene Therapeutics' Q2 2026 results show a significant net loss of $30.2 million, widening from a loss of $25.8 million in Q2 2025. The unchanged zero revenue continues to underscore the company's ongoing challenges in…
Earnings analysis · 10-Q
ENGN earnings analysis
Filed September 8, 2026 · Our reading of the company's report
The latest report
enGene reported a third-quarter loss of $0.47 per share, improving by $0.10 from the $0.57 loss reported in 3Q 2025, although operating expenses increased to $34.0 million. Cash was $266.3 million, but revenue, margins,…
Read full summary
enGene reported a third-quarter loss of $0.47 per share, improving by $0.10 from the $0.57 loss reported in 3Q 2025, although operating expenses increased to $34.0 million. Cash was $266.3 million, but revenue, margins, segment results, cash flow and free cash flow were not disclosed in the provided 10-Q extract. Management maintained its 4Q 2026 clinical-data, FDA-meeting and BLA-submission milestones, supporting a neutral outlook while clinical and regulatory execution risks remain.
Reported figures
- Earnings per share
- $-0.47
What stood out
-
EPS Loss Narrowed Year Over Year
Third-quarter loss was $0.47 per diluted share, narrowing by $0.10 from a $0.57 loss in 3Q 2025 and improving from a $0.57 loss in the prior-year period.
-
Cash Balance Reached $266.3M
Cash and cash equivalents were $266.3 million at quarter-end, providing liquidity for ongoing clinical and regulatory activities.
-
Clinical Investment Increased
Operating expenses increased to $34.0 million, indicating continued investment in clinical development and corporate activities despite the narrower per-share loss.
-
Key 2026-2027 Milestones Reaffirmed
The company reaffirmed a 4Q 2026 data update, a pre-BLA meeting with the FDA, and initiation of the detalimogene BLA submission; a potential FDA approval decision remains planned for 2027.
-
Controls Remediation Completed
Previously identified material weaknesses in internal control over financial reporting were remediated as of October 31, 2025, and disclosure controls were assessed as effective as of July 31, 2026.
What to watch
-
Higher Operating Expense Base
Operating expenses rose to $34.0 million while the company continues to report losses, increasing the rate at which its $266.3 million cash balance may be used.
-
Clinical Data Execution Risk
Final clinical data remains pending, with the next disclosed data milestone targeted for 4Q 2026; delays could affect the planned pre-BLA meeting and BLA submission.
-
Regulatory Timing Uncertainty
The 10-Q does not provide updated risk factors and instead refers investors to the October 31, 2025 Form 10-K. Regulatory execution remains dependent on a planned 2027 FDA approval decision.
Management's outlook
No numeric revenue or EPS guidance was provided in the 10-Q. Management maintained milestones for a 4Q 2026 data update, a pre-BLA meeting with the FDA, and initiation of the detalimogene BLA submission, with a potential FDA approval decision planned for 2027.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.